Cervical Intraepithelial Neoplasia (CIN) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) – Pipeline Review, H2 2017’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN)

The report reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cervical Intraepithelial Neoplasia (CIN) therapeutics and enlists all their major and minor projects

The report assesses Cervical Intraepithelial Neoplasia (CIN) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bioleaders Corp

CEL-SCI Corp

Genexine Inc

Inovio Pharmaceuticals Inc

Novan Inc

PDS Biotechnology Corp

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

THEVAX Genetics Vaccine USA Inc

Transgene SA

Vaccibody AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cervical Intraepithelial Neoplasia (CIN) Overview

Cervical Intraepithelial Neoplasia (CIN) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cervical Intraepithelial Neoplasia (CIN) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cervical Intraepithelial Neoplasia (CIN) Companies Involved in Therapeutics Development

Bioleaders Corp

CEL-SCI Corp

Genexine Inc

Inovio Pharmaceuticals Inc

Novan Inc

PDS Biotechnology Corp

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

THEVAX Genetics Vaccine USA Inc

Transgene SA

Vaccibody AS

Cervical Intraepithelial Neoplasia (CIN) Drug Profiles

ABI-1968 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aminolevulinic acid hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSILSB-710c Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Vaccine to Target E7 for HPV Associated Cancers Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLBL-101c Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-188E Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXI-7 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multikine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVN-3100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDS-0101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RKP-00156 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOR-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVGV-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-1016 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vvax-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cervical Intraepithelial Neoplasia (CIN) Dormant Projects

Cervical Intraepithelial Neoplasia (CIN) Discontinued Products

Cervical Intraepithelial Neoplasia (CIN) Product Development Milestones

Featured News & Press Releases

Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer

Mar 23, 2017: Vaccibody Announces Vaccination Of First Patient In Its Phase IIA Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix

Mar 02, 2017: Vaccibody Announces Approval Of Amendment Of IMPD Allowing To Start Of Expansion Phase In Its Phase I/IIa Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix

Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed

Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016

Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress

Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet

Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe

Mar 02, 2015: Genexines cervical intraepithelial neoplasia therapeutic "GX-188E" receives approval for Phase II in Europe

Jan 26, 2015: TheVax Genetics Vaccine Announces TVGV-1 Update

Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial

Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology

Mar 12, 2014: Genexine's cervical interaepithelial dysplasia DNA vaccine "GX-188E" receives approval for Phase II

Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by Bioleaders Corp, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by CEL-SCI Corp, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by Genexine Inc, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by Novan Inc, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by PDS Biotechnology Corp, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by Transgene SA, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Pipeline by Vaccibody AS, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Dormant Projects, H2 2017

Cervical Intraepithelial Neoplasia (CIN) Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports